Sudeep Pharma Limited
NSE: SUDEEPPHRMPharmaceuticals
Share price
₹1,114.90
-4.74% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
62
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹12,264 Cr
P/E ratio
67.1
P/B ratio
14.3
ROCE
28.2%
ROE
25.2%
Dividend yield
0.1%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 28.1% a year against a sector median of 13.1% — 15.1 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 1.7 times its growth rate, on earnings growth of 40%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Sudeep Pharma Limited — this one | 40%/yr | 67.1× | ₹1.7 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 16 of 130 on returns, 10 of 127 on growth, 12 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 28.2% on capital, ahead of 88% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the last five years it made ₹230 crore of cash from the business but spent ₹356 crore on plant and equipment, ₹126 crore more than it made; the gap was from lenders and shareholders. But only about 45 of every 100 rupees of profit it reported over 7 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 30 days for its cash to waiting 175 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
8 of 9 checks clear · 89%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue up 27% but profit margin stuck at 34.7%, below the 37-38% management is aiming for
Announced 4 Aug 2026 · Consolidated · Unaudited
Revenue
₹158 Cr
Revenue vs last year
+26.6%
Revenue vs last quarter
-13.0%
Net profit
₹41 Cr
Profit vs last year
+30.9%
Profit vs last quarter
-17.2%
Net margin
25.6%
EPS
₹3.59
Earnings call transcript · 5 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹12,264 Cr
- Prev close
- ₹1,114.90
- 52w High
- ₹1,378
- 52w Low
- ₹524
- Enterprise value
- ₹12,299 Cr
- Beta
- 0.9
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 14.8%
- PEG ratio
- 1.7
- P/E ratio
- 67.1
- P/B ratio
- 14.3
- EV / EBITDA
- 52.8
- Industry P/E
- 38.0
- ROCE
- 28.2%
- ROCE 5y average
- 36.4%
- ROE
- 25.2%
- Debt / Equity
- 0.2
- Interest coverage
- 29.5
- Dividend yield
- 0.1%
- ROE 3y average
- 32.0%
- ROE last year
- 25.0%
Annual P&L
- Annual revenue
- ₹642 Cr
- Annual profit
- ₹174 Cr
- Operating margin
- 35.0%
- Net profit margin
- 27.1%
- EBITDA margin
- 34.7%
- Sales growth 3y
- 14.4%
- Sales growth 5y
- 24.5%
- Profit growth 3y
- 40.0%
- Profit growth 5y
- 39.0%
- EPS
- ₹15.3
- Sales growth TTM
- 24.0%
- Profit growth TTM
- 20.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹158 Cr
- Profit latest quarter
- ₹41 Cr
- YoY quarterly sales growth
- 26.7%
- YoY quarterly profit growth
- 32.3%
- OPM latest quarter
- 34.7%
Balance Sheet
- Book Value
- ₹80.3
- Face Value
- ₹1.0
- Total debt
- ₹150 Cr
- Total cash
- ₹115 Cr
- Borrowings
- ₹150 Cr
- Reserves / Equity
- 79.3
Cash Flow
- Operating cash flow
- ₹70 Cr
- Free cash flow
- -₹49 Cr
- FCF yield
- -0.5%
- Net cash flow
- -₹10 Cr
Shareholding
- Promoter holding
- 76.2%
- FII holding
- 1.8%
- DII holding
- 15.6%
- Public holding
- 6.4%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,750.25 | 33.2 | 4,19,944 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,392.65 | 83.7 | 2,49,345 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,620.15 | 78.8 | 1,75,736 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,118.50 | 23.0 | 1,11,571 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,012.70 | 99.5 | 1,08,749 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,296.00 | 29.3 | 1,04,700 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Dr Reddy's Labs | 1,176.75 | 30.5 | 98,221 | 0.67 | 435.6 | -68.7 | 8,099.8 | -5.5 | 13.0 |
| Sudeep Pharma | 1,106.00 | 68.4 | 12,492 | 0.13 | 40.6 | 31.6 | 158.3 | 26.7 | 28.2 |
| Median | 416.00 | 34.1 | 2,116 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Material Cost | 70 | 70 | 71 | 69 | ||||
| Change in Inventories | -9.54 | -10 | -7.28 | -12 | ||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | 0 | ||||
| Employee Cost | 14 | 15 | 11 | 14 | ||||
| Other Expenses | 32 | 37 | 45 | 32 | ||||
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43 | 34 | 37 | 35 | 34 | 35 | 34 | 35 |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | ||||
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21 | 24 | 24 | 29 | 21 | 23 | 23 | 25 |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 |
| Diluted EPS in Rs | 4.20 | 4.29 | 4.38 | 3.59 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Material Cost | 270 | |||||||
| Change in Inventories | -42 | |||||||
| Purchases of Stock-in-Trade | 0 | |||||||
| Employee Cost | 52 | |||||||
| Other Expenses | 141 | |||||||
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21 | 20 | 20 | 21 | 40 | 38 | 35 | 34 |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Exceptional items (within Other Income) | 0 | |||||||
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 7.60 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 27 | 22 | 27 | 28 | 24 | 24 | 24 | |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS in Rs | 128 | 237 | 356 | 442 | 945 | 14 | 15 | 17 |
| Diluted EPS in Rs | 16 | |||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 24%
- 3 years
- 14%
- TTM
- 24%
Compounded profit growth
- 10 years
- —
- 5 years
- 39%
- 3 years
- 40%
- TTM
- 20%
Return on equity
- 10 years
- —
- 5 years
- 32%
- 3 years
- 32%
- Last year
- 25%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 9.72 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Minority Interest | 15 | ||||||
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,175 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from Financing Activity | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -48 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | 36 | 36 | 33 | 49 | 36 | 28 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
35.00inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Sudeep Pharma Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- calcium hydroxide
- mineral calcium / calcium carbonate
- phosphoric acid
- sodium acid pyrophosphate
- sorbic acid
Depends on the price of
- lpg_propane_butane
Sells to
- Alembic Pharmaceuticals Limited · pharmaceutical excipients / mineral-based ingredients
- Aurobindo Pharma · pharmaceutical excipients / mineral-based ingredients
- Danone · food & nutrition fortification minerals (calcium/iron/magnesium salts)
- Intas Pharmaceuticals · pharmaceutical excipients / mineral-based ingredients
- Mankind Pharma Limited · pharmaceutical, food and nutrition excipients / specialty mineral ingredients
- Merck Group · pharmaceutical excipients / specialty mineral ingredients
- Pfizer Limited · pharmaceutical excipients / mineral-based ingredients
- Torrent Pharmaceuticals · pharmaceutical excipients / mineral-based ingredients
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE0QPI01025
Business segments
- Pharmaceutical, Food and Nutrition · 56%
- Speciality Ingredients · 43%
- Inter Segment Revenue · 1%
Plants
- Ireland Facility / NSS (Manufacturing Facility IV)
- Nandesari Facility I (Manufacturing Facility I)
- Nandesari Facility II (Manufacturing Facility II)
- Poicha Facility (Manufacturing Facility III)
- Upcoming Nandesari greenfield facility
News impact
Big market events that reach Sudeep Pharma Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 23 Jul 2026 | unspecified | ₹1.5 |
|---|
Splits, bonuses & buybacks
- daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 4 Aug 2026 | GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO | BUY | 11,76,472 | ₹850.00 |
| 4 Aug 2026 | NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III | SELL | 6,14,112 | ₹850.00 |
| 24 Jul 2026 | SBI MUTUAL FUND | BUY | 20,00,000 | ₹800.00 |
| 24 Jul 2026 | NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III | SELL | 10,60,000 | ₹800.00 |
| 24 Jul 2026 | NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA | SELL | 9,40,000 | ₹800.00 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY275 Aug 2026
- Annual report · 2025-2610 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2622 May 2026
- Earnings call · Q3FY269 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.